Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/166560
Diabetic Retinopathy and Ocular Melanoma: How far we are?
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Diabetic retinopathy causes vascular damage to retinal neurons, presenting characteristics of chronic inflammation. The development of new therapies capable of combating vision loss involves knowledge of inflammatory retinal changes. Studies in animal models and patients with diabetes have shown a high expression of the inflammatory molecules that are involved in the progression of diabetic retinopathy. Uveal melanoma is an eye tumour that remains highly deadly, because despite the correct treatment, it still causes metastasis in about 50% of patients. This type of tumour has the ability to produce and store melanin, which may result in resistance to therapy. Over time there has been development of new therapies for this disease, such as radiotherapy and surgical resection. In this review, we discuss diabetic retinopathy and ocular melanoma, their relationship with angiogenesis and the current anti-angiogenic therapies for their treatment
Matèries (anglès)
Citació
Citació
SOUTO, Eliana b., CAMPOS, Joana r., DA ANA, Raquel, FANGUEIRO, Joana f., MARTINS-GOMES, Carlos, DURAZZO, Alessandra, LUCARINI, Massimo, SÁNCHEZ-LÓPEZ, E. (elena), ESPINA GARCÍA, Marta, GARCÍA LÓPEZ, María luisa, SILVA, Amélia m., MENDONÇA, Fernando, SANTINI, Antonello, SOUTO, Selma b.. Diabetic Retinopathy and Ocular Melanoma: How far we are?. _Applied Sciences_. 2020. Vol. 10, núm. 2777-. [consulta: 26 de febrer de 2026]. ISSN: 2076-3417. [Disponible a: https://hdl.handle.net/2445/166560]